Field | Value |
---|---|
Data last updated | December 5, 2024 |
Metadata last updated | December 5, 2024 |
Created | December 5, 2024 |
Format | CSV |
License | Open Government Licence 3.0 (United Kingdom) |
Column | Title | Type | Description |
---|---|---|---|
ODS_CODE | Organisation Data Service code for pharmacy, appliance, or local pharmaceutical services contractor | string | The Organisation Data Service (ODS) code of the premises at which pharmaceutical services may be provided |
PHARMACY_NAME | Trading name of contractor | string | The name under which a pharmacy contractor, appliance contractor, or local pharmaceutical services contractor trades |
ICB_NAME | Integrated Care Board (ICB) Name | string | The name given to a geographical statutory organisation by NHS England that is a smaller division of a region |
ICB_CODE | Integrated Care Board (ICB) Code | string | Integrated Care Board (ICB) Code |
Q1 | A question asked whilst completing the quality domain in the PQS declaration on MYS | string | Do you want to claim for the Respiratory domain? Answers: yes / no Mandatory |
Q2 | A question asked whilst completing the quality domain in the PQS declaration on MYS | string | Can you evidence that between 1 June 2023 and the day of the declaration, the pharmacy has checked that all children aged 5 to 15 prescribed a press and breathe pressurised MDI for asthma have a spacer device, where appropriate, in line with NICE TA38 and referred children aged 5 to 15 with asthma to an appropriate healthcare professional where this is not the case? Answers: yes / no (N/A where question was not asked) Mandatory |
Q3 | A question asked whilst completing the quality domain in the PQS declaration on MYS | string | The pharmacy must have a process in place to identify and refer patients with asthma who had 3 or more short-acting bronchodilator inhalers dispensed without any corticosteroid inhaler within a 6-month period.Can you evidence that this process was in place between 1 June 2023 and the day of the declaration, and that these cases were referred to an appropriate healthcare professional for an asthma review? Answers: yes / no (N/A where question was not asked) Mandatory |
Q4 | A question asked whilst completing the quality domain in the PQS declaration on MYS | string | Can you evidence that between 1 June 2023 and the day of the declaration, the pharmacy had a process in place to have conversations about the safe and environmentally friendly disposal of inhalers with patients, their carers or their representatives? Answers: yes / no (N/A where question was not asked) Mandatory |
Q5 | A question asked whilst completing the quality domain in the PQS declaration on MYS | string | By the end of 31 March 2024, will you be able to evidence that the pharmacy has checked that all patients aged 5 and above who have been dispensed an inhaler for asthma between 1 June 2023 and the day of the declaration have a Personalised Asthma Action Plan (PAAP)? Answers: yes / no (N/A where question was not asked) Mandatory |
Q6 | A question asked whilst completing the quality domain in the PQS declaration on MYS | string | By the end of 31 March 2024, will all patient-facing staff working at your pharmacy on the day of the declaration have been trained on the reasons why used, unwanted and expired inhalers should be returned to the pharmacy for safe disposal, and the adverse effects of the environment when inhalers are disposed of in domestic waste? Answers: yes / no (N/A where question was not asked) Mandatory |
Q7 | A question asked whilst completing the quality domain in the PQS declaration on MYS | string | Between 1 April 2020 and the end of 31 March 2024, will all pharmacists working at the pharmacy on the day of the declaration have satisfactorily completed the 'CPPE inhaler technique for health professionals: getting it right' e-learning or attended a CPPE face-to-face inhaler technique workshop, and passed the Inhaler technique for health professionals e-assessment? Answers: yes / no (N/A where question was not asked) Mandatory |